CMM Offers Advanced Test

November 16, 2007
Text Size:

GRAND RAPIDS — The Center for Molecular Medicine is one of the first laboratories in the Midwest to offer the Veridex CellSearch Systems to physicians with patients suffering from metastatic, or advanced, breast cancer.

CellSearch is the first diagnostic test to automatically identify and count circulating tumor cells in the bloodstream from a blood sample. According to CMM, studies have shown that if five or more circulating tumor cells are present in a patient’s blood sample, overall survival is shorter than for those with a CTC value below five cells.     

Editor's Picks

Comments powered by Disqus